Planning
Friday, December 11, 2020
| Time |
Event |
|
|
09:00 - 09:05
|
Welcome speech |
|
|
09:05 - 11:15
|
Oral session |
|
|
09:05 - 09:25
|
DNA pathways inhibitors - Marie Dutreix, Institut Curie, Orsay |
|
|
09:25 - 09:45
|
Radiotherapie potentiation from microenvironnement - Fernanda Herrera, CHUV, Lausane |
|
|
09:45 - 10:05
|
Nanoparticles - A French staut-up: from bench to clinical assays - Olivier Tillement, NH TherAguix, Lyon |
|
|
10:05 - 10:15
|
Break |
|
|
10:15 - 10:40
|
AstraZeneca - Strategic gaps - Dr Marisol URBIETA, Directeur Médical Oncologie France, AstraZeneca France |
|
|
10:40 - 11:05
|
Evaluation des théranostiques de la préclinique à la clinique - Cyril Berthet - Oncodesign |
|
|
11:05 - 11:15
|
Unitrad work group propositions - Stéphane Supiot, Institut de Cancérologie de L'Ouest, Nantes |
|
|
11:15 - 11:20
|
Break |
|
|
11:20 - 12:20
|
Round Tables |
|
|
11:20 - 12:20
|
Direct poptentiation of RT - C. Rodriguez-Lafrasse - E. Porcel - J.N. Badel |
|
|
11:20 - 12:20
|
RT potentiation from microenvironnement - E. Deutsch/E. Cohen-Moyal/ S. Supiot |
|
|
11:20 - 12:20
|
Preclinical assay optimisation - S. Valable/ S. Pinel |
|
|
12:20 - 12:30
|
Break |
|
|
12:30 - 13:00
|
Restitution - S. Supiot, S. Pinel, J.N. Badel |
|
|
Loading...